<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00473577</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC 0401</org_study_id>
    <nct_id>NCT00473577</nct_id>
  </id_info>
  <brief_title>Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients</brief_title>
  <official_title>Two Phase, Open-Label, Sequential, Ascending Dose Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the maximum tolerated dose (MTD) of CRA-024781 IV given by 2-hour intravenous&#xD;
      infusions in patients with refractory solid or hematologic malignancies. To evaluate safety&#xD;
      and tolerability, pharmacokinetics and pharmacodynamics, and to evaluate bioavailability of&#xD;
      CRA-024781 IV when administered in a single oral dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive a single oral dose of CRA-024781 one week before beginning intravenous&#xD;
      dosing. Blood samples for pharmacokinetic and pharmacodynamic analysis will be collected on&#xD;
      several occasions prior to the start of the intravenous treatment.&#xD;
&#xD;
      The intravenous treatment will consist of 3 consecutive days of CRA-024781 IV administered as&#xD;
      a 2-hour IV infusion every 3 weeks in a 4 weeks cycle.&#xD;
&#xD;
      Assessment of the extent of disease will be performed every 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <condition>Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRA-24781</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  histologically confirmed solid or hematologic malignancy that is refractory to&#xD;
             standard therapy or for which no standard therapy exists&#xD;
&#xD;
          -  estimated life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  ECOG performance grade ≤ 2&#xD;
&#xD;
          -  creatinine ≤ 1.5 X institutional upper limit of normal or creatinine clearance &gt; 50&#xD;
             mL/min&#xD;
&#xD;
          -  total bilirubin within institutional limits (unless elevated from documented Gilbert's&#xD;
             syndrome)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 X institutional upper limit of normal (≤ 5 x institutional upper&#xD;
             limit of normal in the presence of liver metastases)&#xD;
&#xD;
          -  platelet count ≥ 100,000/µL&#xD;
&#xD;
          -  absolute neutrophil count (ANC) ≥ 1500/µL&#xD;
&#xD;
          -  Hgb ≥ 9.0 g/dL&#xD;
&#xD;
          -  patients with previously treated brain metastases who are not on corticosteroids are&#xD;
             eligible&#xD;
&#xD;
          -  effective contraceptive method (e.g., intrauterine device, oral contraceptive, or&#xD;
             barrier device) must be used during the study by male and female patients of&#xD;
             childbearing potential&#xD;
&#xD;
          -  ability to understand and willingness to sign a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients who have had immunotherapy, chemotherapy, or radiotherapy within 4 weeks&#xD;
             (within 6 weeks for nitrosoureas or mitomycin C) prior to study entry; study entry&#xD;
             defined as first day of drug dosing&#xD;
&#xD;
          -  patients who have undergone major surgery within 4 weeks prior to study entry&#xD;
&#xD;
          -  patients who are receiving another investigational drug&#xD;
&#xD;
          -  patients with active CNS metastases or leptomeningeal disease not controlled by prior&#xD;
             surgery or radiotherapy&#xD;
&#xD;
          -  uncontrolled illness including but not limited to: ongoing or active infection,&#xD;
             symptomatic congestive heart failure (New York Heart Association Class III or IV heart&#xD;
             failure), unstable angina pectoris, cardiac arrhythmia, and psychiatric illness that&#xD;
             would limit compliance with study requirements&#xD;
&#xD;
          -  risk factors for QTc prolongation and/or Torsade de Pointes&#xD;
&#xD;
          -  patients with known HIV infection&#xD;
&#xD;
          -  concurrent systemic hormonal therapy except: stable LHRH agonist therapy for prostate&#xD;
             cancer; hormonal therapy (e.g., megestrol) for appetite stimulation; nasal,&#xD;
             ophthalmic, and topical glucocorticoid preparations when appropriate; stable oral&#xD;
             glucocorticoid and mineralocorticoid replacement for adrenal insufficiency; or oral&#xD;
             contraceptives&#xD;
&#xD;
          -  patients who have other medical or psychiatric illness or organ dysfunction which, in&#xD;
             the opinion of the Investigator, would either compromise the patient's safety or&#xD;
             interfere with the evaluation of the safety of the study agent&#xD;
&#xD;
          -  pregnant or lactating women (female patients must have a negative serum pregnancy test&#xD;
             within 7 days of study entry)&#xD;
&#xD;
          -  patients who have previously received histone deacetylase inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Samir Undevia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60643</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pharmacyclics.com</url>
    <description>Pharmacyclics</description>
  </link>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>May 11, 2007</study_first_submitted>
  <study_first_submitted_qc>May 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2007</study_first_posted>
  <last_update_submitted>August 24, 2010</last_update_submitted>
  <last_update_submitted_qc>August 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

